This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

Anthony G.:

I am entirely disappointed in your article about CPRX. You have caused my family a lot of heartache and destroyed our weekend. I guess your mother never told you that if you didn't have anything nice to say don't say anything at all. spend your time (and your political science degree?????) promoting good investments and not bashing what you perceive to be bad ones. This is the second time one of your lame brain articles has cost me money. Hope you and your buddies have fun spending all the money you guys made by shorting the stock.

I mentioned above that some of the Catalyst longs have taken to various message boards to cyber-bully and attack the LEMS patient interviewed in one of my stories. Apparently, it's now acceptable to smear a 74-year-old man with a horrible disease because you lost money in the stock market.

Attacking me is fine. I'm used to it. Going after a LEMS patient courageous enough to tell his story -- and to do so using the anonymity of the Internet -- is cowardly and disgusting.

Instead of condemning these attacks, Catalyst longs took to Twitter to make yet more excuses:

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $4.61 0.00%
CPRX $1.69 0.00%
ONTX $0.46 0.00%
SRPT $11.18 0.00%
VNDA $7.99 0.00%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs